InterGlobe Aviation Leads Weekly Gains; Pharma and Banking Stocks Rally on Broker Upgrades and Policy Tailwinds

Mumbai, June 28: Markets saw a strong rotation into select large-cap names during the week, with sector-specific triggers driving sharp stock-level moves across aviation, pharmaceuticals and banking. Falling crude oil prices provided a major tailwind for airline stocks, while pharma names saw gains on positive brokerage commentary and improving visibility in key overseas markets. Banking stocks also benefited from supportive regulatory cues and a softer interest-rate outlook, helping reinforce expectations of stable earnings momentum across the financial sector. Against this backdrop, InterGlobe Aviation emerged as the standout performer, while Dr. Reddy’s Laboratories, Cipla and ICICI Bank also featured among the week’s notable gainers on stock-specific catalysts.

InterGlobe Aviation: InterGlobe Aviation share price rose 8.74% during the week gone by to Rs 5,450 clocking a market cap of Rs 2,10,704 crore.

Shares of the IndiGo operator emerged as the week’s biggest gainer, buoyed by a sharp correction in crude oil prices that improved the earnings outlook for airlines by lowering aviation turbine fuel (ATF) costs, one of the industry’s largest operating expenses. The stock also drew support from optimism around the carrier’s industry-leading domestic market share, healthy passenger demand and aggressive international expansion strategy. Investor confidence has also been underpinned by expectations that a benign fuel-cost environment and disciplined capacity additions could help protect margins even as competition intensifies.

Looking ahead, the stock is likely to remain sensitive to movements in global crude prices, monthly passenger traffic data, yield and fare trends, capacity deployment by rival airlines and any fresh commentary from management or brokerages on demand, profitability and expansion plans. Any further signs of stable fuel prices and sustained travel demand could provide additional support to the stock, while a rebound in oil prices or aggressive pricing competition may temper sentiment.

Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories share price rose 6.55% during the week gone by to Rs 1,351 clocking a market cap of Rs 1,12,720 crore.

Shares of the pharmaceutical major gained during the week after brokerage Nomura reiterated its ‘Buy’ rating and raised its target price to Rs 1,740. The brokerage said the company’s strategic pivot toward higher-margin branded generics and consumer healthcare, supported by recent acquisitions and management restructuring, could improve earnings quality and warrant a valuation re-rating. Nomura expects branded products to account for nearly 60% of the revenue mix by 2028-29, up from 48% in FY22, reducing dependence on the more volatile U.S. generics business. While the brokerage expects near-term selling and distribution costs to rise as the company expands its commercial footprint, it believes a richer product mix, stronger market positioning and opportunities in biosimilars and GLP-1 therapies will more than offset the higher spending over time.

Looking ahead, investors will watch for further brokerage commentary, regulatory and product development updates, and any signs of progress in the company’s branded business strategy, which could determine whether the recent momentum in the stock continues.

Cipla: Cipla share price rose 6.24% during the week gone by to Rs 1,440 clocking a market cap of Rs 1,16,329 crore.

Shares of the pharma major were among the week’s top Nifty gainers, rising sharply after brokerage Citi turned constructive and placed the stock on a 90-day Positive Catalyst Watch, reiterating its ‘Buy’ rating. The brokerage highlighted a series of near-term U.S. triggers that could support earnings momentum, including expected approvals and launches of key respiratory products such as gFlovent and gVentolin, along with Cipla’s strong positioning in niche molecules like Nintedanib. Citi also pointed to improving prospects in the domestic respiratory portfolio, which has been seeing steady traction, and flagged the upcoming USFDA re-inspection of the Indore facility as a potential additional upside trigger if it results in clearance. The overall view suggests a possible rebound in Cipla’s U.S. revenues after a period of softness, aided by both product pipeline visibility and regulatory catalysts.

Looking ahead, investor focus will remain on updates around U.S. product approvals, domestic respiratory demand trends, inspection outcomes, and any further brokerage revisions, which could determine whether the stock sustains its recent outperformance.

ICICI Bank: ICICI Bank share price rose 3.37% during the week gone by to Rs 1,388, clocking a market cap of Rs 9,93,466 crore.

Shares of the private lender were among the week’s top gainers after regulatory and macro cues turned supportive for the banking space. Sentiment was lifted by the Reserve Bank of India’s decision allowing banks to offer loans against foreign-currency deposits, a move seen as potentially unlocking additional liquidity and improving product flexibility for lenders with strong NRI and forex-linked deposit bases. Adding to the positive tone, RBI Governor Sanjay Malhotra’s remarks ruling out any near-term rate hike further eased concerns around funding cost pressures and interest rate volatility, supporting expectations of stable net interest margins for banks. The combination of regulatory easing and a more benign rate outlook helped reinforce optimism around credit growth visibility and balance sheet strength, with ICICI Bank benefiting as one of the sector’s key large-cap plays.

Looking ahead, investors will watch credit growth trends, deposit accretion, margin trajectory and any further policy signals from the RBI, which could determine whether the stock sustains its recent momentum.

Source: NSE